Engimmune Therapeutics raises CHF 15.5m in a Seed Financing

Engimmune Therapeutics, a Swiss biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, has closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo Holdings with incubation from BaseLaunch. The proceeds will be used to grow and develop T-cell receptor-based therapies for cancer treatments, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.

Engimmune is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. By combining genome editing, functional screening, deep sequencing and machine learning, Engimmune addresses major efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapies.

Engimmune is a spinout from the lab of Prof Sai Reddy at ETH Zurich and Dr Rodrigo Vazquez-Lombardi, co-inventor of the company’s platform technologies, who is now its Chief Scientific Officer. The company was initially incubated and financed through BaseLaunch, a Switzerland-based incubator and accelerator. The seed round is funded by Pureos Bioventures, a Swiss venture capital fund investing in innovative drug development companies and Novo Seeds, the early-stage investment and company creation team of Novo Holdings.

The company also announces the appointment of TCR pioneer and industry veteran Dr Bent Jakobsen as Chairman of the Board. Former chief scientist and co-founder of Immunocore, a soluble TCR therapeutics company, and Adaptimmune, an adoptive TCR-T cell therapy company, Dr Jakobsen is a global expert in the field of T cell immunology.

The VISCHER corporate/m&a team advising the investors in this transaction included Matthias Staehelin (partner, pictured), Vincent S. Reardon (managing associate) and Pauline Pfirter (associate).

Engimmune Therapeutics raises CHF 15.5m in a Seed Financing

mercedes.galan@lcpublishinggroup.it

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC srl – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 10.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram